Make an Inquiry
Accelerating Stargardt Disease Drug Development

Stargardt disease presents significant therapeutic challenges due to its complex genetic etiology and progressive retinal degeneration, with limited treatment options currently available. Protheragen stands as a specialized partner in the development of novel therapeutics targeting Stargardt disease, offering a full spectrum of preclinical drug development capabilities. From target validation and lead optimization to IND-enabling studies, Protheragen delivers integrated solutions designed to advance drug candidates efficiently and effectively. Leveraging deep scientific expertise and advanced technology platforms, Protheragen ensures rigorous evaluation of candidate molecules, robust preclinical modeling, and comprehensive pharmacology and toxicology assessments. All processes are conducted in strict adherence to global regulatory standards, supporting the seamless transition of promising therapies into clinical development. Protheragen’s commitment to scientific excellence and regulatory compliance positions the company as a trusted collaborator for organizations seeking to address the unmet medical needs of Stargardt disease patients. By accelerating the path from discovery to clinical readiness, Protheragen is dedicated to enabling therapeutic breakthroughs that have the potential to transform patient outcomes.

What is Stargardt DiseaseTargets for Stargardt DiseaseDrug Discovery and Development ServicesWhy Choose Us

What is Stargardt Disease

Stargardt disease is an inherited retinal disorder characterized by progressive degeneration of the macula, the central area of the retina responsible for sharp, central vision. Most commonly caused by biallelic mutations in the ABCA4 gene, the disease leads to impaired transport of retinoids within photoreceptor cells. This dysfunction results in the accumulation of toxic bisretinoid compounds, particularly lipofuscin, within the retinal pigment epithelium (RPE), ultimately causing photoreceptor cell death and central vision loss. While classic Stargardt disease presents in childhood or adolescence, later-onset and Stargardt-like forms linked to other genes, such as ELOVL4, PROM1, and PRPH2, have also been described. Clinically, Stargardt disease manifests as progressive, bilateral central vision loss, often accompanied by difficulties with color vision and reading, while peripheral vision is typically preserved. Diagnosis relies on a combination of clinical history, fundus examination revealing characteristic yellow-white flecks and macular atrophy, advanced retinal imaging techniques, and confirmatory genetic testing. Fundus autofluorescence and optical coherence tomography (OCT) are particularly helpful in assessing retinal changes. Currently, there is no cure or approved disease-modifying therapy for Stargardt disease; management focuses on visual rehabilitation, low vision aids, and genetic counseling. Ongoing research aims to develop gene therapies and pharmacological interventions to slow disease progression.

Learn More

Targets for Stargardt Disease

Targets in Clinical or Later Phases of Development

Target Name Gene Symbol
retinoid isomerohydrolase RPE65 RPE65
retinol binding protein 4 RBP4
Gastric H+/K+-ATPase
complement C5 C5
acetylcholinesterase (Yt blood group) ACHE

Stargardt disease is primarily driven by dysfunction in the visual cycle and retinoid transport, with several molecular targets playing critical roles in disease pathogenesis. The most important of these is ABCA4, a photoreceptor-specific transporter whose mutations cause toxic bisretinoid accumulation and subsequent retinal degeneration. RPE65, an essential isomerase in the retinal pigment epithelium, is also implicated due to its role in regenerating the visual chromophore, with its activity affected downstream of ABCA4 dysfunction. Retinol Binding Protein 4 (RBP4) and Transthyretin (TTR) are key mediators of systemic and retinal vitamin A transport, influencing the substrate availability for toxic byproduct formation. Retinoic Acid Receptor Alpha (RARA) regulates gene expression in response to retinoic acid, linking altered retinoid metabolism to changes in retinal cell health and survival. Therapeutic strategies are being developed to target these proteins and restore retinal homeostasis. Gene augmentation therapies for ABCA4 are in preclinical and early clinical development, aiming to correct the underlying genetic defect. RPE65 is already a validated target for gene therapy in related retinal diseases, and visual cycle modulators are under investigation to indirectly influence its activity in Stargardt disease. Small-molecule inhibitors of RBP4, such as fenretinide, have shown promise in reducing toxic bisretinoid accumulation in preclinical models. While direct modulation of RARA and TTR remains exploratory, their involvement in retinoid signaling and transport positions them as potential future therapeutic targets. Collectively, these approaches offer hope for slowing disease progression and preserving vision in affected individuals.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service accelerates Stargardt disease drug discovery by offering robust, sensitive platforms to assess candidate therapies targeting key proteins and pathways. Utilizing bioluminescent, chemiluminescent, fluorescent, radioactivity-based, and ELISA assays, we evaluate compound potency, efficacy, and mechanism of action. We measure critical pharmacological parameters such as EC-50, IC-50, Kd, and Ki across targets including ABCA4, RPE65, RBP4, and complement factors. Our comprehensive approach enables precise quantification of enzyme activities, binding affinities, and pathway modulation, supporting informed lead selection and optimization for effective Stargardt disease therapeutics.

Angiotensin I Converting Enzyme Atp Binding Cassette Subfamily B Member 11
Complement C5 Complement Factor D
Cytochrome P450 Family 26 Subfamily A Member 1 Retinoid Isomerohydrolase Rpe65
Retinol Binding Protein 4 Transthyretin

Learn More

Why Choose Us

Choosing Protheragen for your Stargardt disease drug development projects means partnering with a team deeply specialized in this challenging therapeutic area. At Protheragen, we combine extensive expertise in Stargardt disease research with a proven ability to translate scientific discoveries into promising drug candidates. Our professional teams are supported by advanced technology platforms, enabling us to deliver cutting-edge solutions tailored to the unique needs of Stargardt disease. Protheragen’s track record in preclinical drug development is built on reliability, with numerous successful collaborations and a strong reputation for delivering results on time and within scope. We adhere to the highest quality standards and maintain rigorous regulatory compliance at every stage of our process, ensuring that every project meets both scientific and regulatory expectations. Most importantly, Protheragen is committed to advancing therapeutics for Stargardt disease, working closely with our partners to bring hope and innovative treatments to patients. When you choose Protheragen, you gain a dedicated ally focused on excellence, integrity, and real progress in the fight against Stargardt disease.

FAQs for Our Services

Q: What are the main preclinical research challenges specific to developing drugs for Stargardt disease?

A: Stargardt disease poses unique preclinical research challenges, including the limited availability of relevant animal models that accurately recapitulate the human disease phenotype, especially the progressive retinal degeneration seen in patients. Additionally, the slow progression and variability of the disease complicate the assessment of drug efficacy in preclinical studies. Our company addresses these challenges by utilizing advanced in vivo and in vitro models, including genetically engineered mouse models and patient-derived retinal organoids, to closely mimic disease mechanisms and enable robust preclinical evaluation.

Q: What are the key regulatory considerations for Stargardt disease drug development in the preclinical phase?

A: Regulatory agencies such as the FDA and EMA require comprehensive preclinical data to support the safety and efficacy of drug candidates for Stargardt disease. This includes pharmacokinetics, toxicology, and proof-of-concept efficacy studies in relevant models. There is also a strong emphasis on demonstrating translational relevance to the human condition. Our team has extensive experience designing preclinical programs that align with regulatory guidelines and can assist with regulatory submissions, including IND-enabling studies and orphan drug designation applications.

Q: What technical aspects should be considered during preclinical research for Stargardt disease?

A: Critical technical aspects include the selection and validation of disease models, sensitive and quantitative methods for assessing retinal structure and function (such as OCT, ERG, and histopathology), and the development of biomarkers for early detection of therapeutic effects. Our company offers a comprehensive suite of technical services, including advanced imaging, molecular analyses, and customized assay development, to ensure high-quality and reproducible preclinical data.

Q: What are the typical timeline and cost considerations for preclinical drug development targeting Stargardt disease?

A: The preclinical phase for Stargardt disease drug development typically spans 12 to 24 months, depending on the complexity of the program and the models used. Costs can vary widely, but comprehensive preclinical packages—including efficacy, safety, and pharmacokinetic studies—generally range from $1 million to $3 million. Our company provides detailed project planning and transparent budgeting to help clients optimize timelines and manage costs effectively while maintaining scientific rigor.

Q: What are the critical success factors in preclinical drug development for Stargardt disease?

A: Key success factors include the selection of appropriate and predictive disease models, rigorous study design, early engagement with regulatory authorities, and the integration of translational biomarkers. Additionally, close collaboration between multidisciplinary teams—spanning pharmacology, toxicology, and ophthalmology—is essential. Our expertise in preclinical ophthalmic drug development, combined with our track record of successful IND submissions, positions us to support clients in achieving these success factors and advancing their Stargardt disease therapies toward clinical development.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © 2025 Protheragen. All rights reserved.